Aripiprazole and Resistant Postpartum Depression
Verified April 2015 by Lawson Health Research Institute
Information provided by (Responsible Party):
Verinder Sharma, Lawson Health Research Institute
First received: April 21, 2011
Last updated: April 2, 2015
Last verified: April 2015
Currently there are no controlled data on the management of postpartum depression that fails to respond to adequate antidepressant therapy. The investigators recently reported that a large number of patients responded to the addition of atypical neuroleptics after having failed antidepressant trials. Aripiprazole used adjunctively to antidepressants is effective in patients with resistant depression but it has not been studied in patients with resistant postpartum depression. The investigators propose to conduct a 6 week open-label study to assess the effectiveness and tolerability of aripiprazole used adjunctively to antidepressants in patients with resistant postpartum depression.
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Augmentation Therapy of Resistant Postpartum Depression With Aripiprazole
Primary Outcome Measures:
Secondary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Primary Completion Date:
||November 2013 (Final data collection date for primary outcome measure)
aripiprazole used adjunctively to antidepressants in patients with resistant postpartum depression
The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
|Ages Eligible for Study:
||18 Years to 45 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Euthyroid outpatients aged 18 to 45 years of age
- A DSM-IV diagnosis of major depressive disorder with episode onset within 3 months of delivery
- A 17-item HAM-D score of 18 or more
Inadequate response to at least one antidepressant drug - defined as a <50% reduction in severity of depression for a duration of >6 weeks ( > than 8 weeks for fluoxetine), determined by the Massachusetts General Hospital Antidepressant Response Questionnaire. Patients having a score of 18 or more on the 17-item HAM-D will be eligible to participate in the study. The primary efficacy endpoint will be mean change in MADRS score, and the secondary endpoint will be mean change in the HAM-D score
>For patients on psychotropic drugs (other than antidepressants) prior there will be a washout period of two weeks
- Ability to understand English and provide informed consent
- Women who delivered a healthy baby close to term (37-42 weeks)
- Use of adequate contraception > Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 4 weeks after the last dose of study drug to minimize the risk of pregnancy. Prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.
WOCBP include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who is not post-menopausal.
Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or who are practicing abstinence or where their partner is sterile (eg, vasectomy) should be considered to be of childbearing potential.
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days before the start of the investigational product.
A subject's male partner of fathering potential must use an adequate method of contraception to avoid conception throughout the study [and for at least 4 weeks after the last dose of study drug] to minimize the risk of pregnancy.
- Women with onset of major depressive disorder during pregnancy
- Presence of another current Axis I disorder such as bipolar disorder, psychotic disorder or obsessive compulsive disorder or a history of psychosis or a history of post-partum mood disorder with psychotic features
- Presence of psychotic symptoms
- History of alcohol or substance abuse within the 12 months before screening
- Any Axis II diagnosis suggestive of likely non-compliance with study requirement or non-responsiveness to pharmacotherapy.
- Women receiving psychotherapy
- Women receiving psychotropic drugs not allowed in the study protocol
- Use of quinolone antibiotics such as ciprofloxacin
- Significant medical illness such as end stage renal disease, uncontrolled narrow angle glaucoma and liver disease
- Women considered at high risk for suicide-those that are actively suicidal or have a score of ≥ 3 on item #3 on the 17-item HAMD; or women who, in the opinion of the Investigator, are deemed to be at risk of causing harm to the baby
- Women who are nursing/breastfeeding
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01386086
|Regional Mental Health Care
|London, Ontario, Canada, N6A4H1 |
|Contact: Verinder Sharma, MBBS 519-455-5110 ext 47600 firstname.lastname@example.org |
|Principal Investigator: Verinder Sharma, MBBS |
Lawson Health Research Institute
||Verinder Sharma, MBBS
||University of Western Ontario, Canada
No publications provided
||Verinder Sharma, Psychiatrist, Lawson Health Research Institute
History of Changes
|Other Study ID Numbers:
|Study First Received:
||April 21, 2011
||April 2, 2015
||Canada: Health Canada
Keywords provided by Lawson Health Research Institute:
major depressive disorder
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 21, 2015
Central Nervous System Agents
Central Nervous System Depressants
Physiological Effects of Drugs